The new CEO already has several years of experience heading the development of allogeneic dendritic cell therapy at DCprime. Hence, he is a logical candidate, and the transition should be smooth, in our opinion.
We do not make any changes to our valuation at this point. We expect the shares to trade sideways in the near term until further news, e.g., an anticipated update regarding the combined business and development plan and the financing strategy.
Aktuellt
SENASTE
